Literature DB >> 15752560

HIV and human complement: inefficient virolysis and effective adherence.

Zoltán Bánki1, Heribert Stoiber, Manfred P Dierich.   

Abstract

Both, HIV envelope proteins gp120 and gp41 can directly activate complement system, even in the absence of HIV-specific antibodies. During the budding process HIV acquires host membrane-associated molecules among these complement regulatory proteins (CRPs). The presence of CRPs on the viral surface rescues HIV from complement-mediated virolysis. The inefficient virolysis results in the deposition of complement-fragments on the viral surface allowing interactions of HIV with complement receptor expressing cells. In this review, the interaction of HIV with the complement system and the consequences of complement opsonisation on virus infection will be discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15752560     DOI: 10.1016/j.imlet.2004.11.007

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  13 in total

1.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

2.  Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.

Authors:  R Herrero; L M Real; A Rivero-Juárez; J A Pineda; Á Camacho; J Macías; M Laplana; P Konieczny; F J Márquez; J C Souto; J M Soria; I Saulle; S Lo Caputo; M Biasin; A Rivero; J Fibla; A Caruz
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

3.  A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement.

Authors:  Leili Jia; Yuanyong Xu; Chuanfu Zhang; Yong Wang; Huihui Chong; Shaofu Qiu; Ligui Wang; Yanwei Zhong; Weijing Liu; Yansong Sun; Fei Qiao; Stephen Tomlinson; Hongbin Song; Yusen Zhou; Yuxian He
Journal:  Virol J       Date:  2010-06-29       Impact factor: 4.099

4.  HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway.

Authors:  Hugues Fausther-Bovendo; Vincent Vieillard; Sandrine Sagan; Georges Bismuth; Patrice Debré
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

5.  Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization.

Authors:  Mohammad-Ali Jenabian; Héla Saïdi; Charlotte Charpentier; Hicham Bouhlal; Dominique Schols; Jan Balzarini; Thomas W Bell; Guido Vanham; Laurent Bélec
Journal:  AIDS Res Ther       Date:  2010-06-14       Impact factor: 2.250

6.  The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization.

Authors:  John B Johnson; Ken Grant; Griffith D Parks
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

7.  A novel approach to inhibit HIV-1 infection and enhance lysis of HIV by a targeted activator of complement.

Authors:  Yuanyong Xu; Chuanfu Zhang; Leili Jia; Cuirong Wen; Huihui Liu; Yong Wang; Yansong Sun; Liuyu Huang; Yusen Zhou; Hongbin Song
Journal:  Virol J       Date:  2009-08-12       Impact factor: 4.099

8.  Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection.

Authors:  Michael Huber; Marek Fischer; Benjamin Misselwitz; Amapola Manrique; Herbert Kuster; Barbara Niederöst; Rainer Weber; Viktor von Wyl; Huldrych F Günthard; Alexandra Trkola
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

Review 9.  Non-Neutralizing Antibodies Directed against HIV and Their Functions.

Authors:  Luzia M Mayr; Bin Su; Christiane Moog
Journal:  Front Immunol       Date:  2017-11-20       Impact factor: 7.561

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.